Dr. Terrence J. Bradley, MD

Dr. Bradley practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Bradley's NPI, 1134495021, was assigned on March 26, 2012. Dr. Bradley graduated from SUNY Downstate Health Sciences University in 2012. Dr. Bradley holds Florida license ME137418.

Dr. Bradley's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Bradley's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Bradley is also affiliated with Jackson Memorial Hospital. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bradley practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Bradley's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Bradley is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Bradley's licenses on file in 2 states: Florida and New York.

Dmand AI lists breast cancer, chronic leukemia and colorectal cancer among the conditions Dr. Bradley treats.

CMS data shows 379 Medicare services from Dr. Bradley across 3 procedure codes in 2024, for 90 Medicare patients. Medicare paid $37,162 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 90 Medicare patients who saw Dr. Bradley in 2024. The largest group is 65 to 74, with 36 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 30% are also on Medicaid. Their average risk score is 3.32, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bradley's median patient age at 71, with 44% women.

In 2024, Dr. Bradley wrote 417 Medicare Part D claims for 67 patients. 49% of them were for generic drugs. CMS names the drug for 233 of them, across 14 drugs with 11 or more claims each, at $2,311,765 in total drug cost. In 2023, CMS named 115 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Bradley for performance year 2024, reported as part of a group. Dr. Bradley accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bradley as offering telehealth.

Dmand AI links 17 papers to Dr. Bradley, published from 2020 to 2025. 2022 was the busiest year, with 5. The most frequent topics are Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols and Cell Line, Tumor. Dr. Bradley has published most often in Blood Adv. Dr. Bradley's most frequent co-authors are Justin M. Watts, MD, Justin W. Taylor, MD and Sunil Girish Iyer, MD.

Dmand AI links Dr. Bradley to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Thrombocythemia, Essential and Thrombocytosis.

CMS Open Payments shows 579 general payments to Dr. Bradley from 33 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 58% of the total. Novartis Pharmaceuticals Corporation paid the most, $27,129. It also lists 2 research payments totaling $155 from 2018 to 2020.

Dr. Bradley graduated from SUNY Downstate Health Sciences University in 2012.

Dr. Bradley is in network with 12 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.